Администрация президента США празднует налоговую победу. Хедж-фондам тоже стоило бы, хотя они могут лишиться возможности налогового маневра
Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA
Red-state Democrats like the West Virginia senator should have been putty in the president’s hands. Instead, he’s alienated them to the point that he’s neither feared nor loved.
Some stocks don’t have much to brag about over the past couple of years and below we look at one of them! Mylan (MYL) has had a rough go of it the past two years as it lost nearly 50% of its value. During this decline could a pattern opportunity have formed. Possibly! Below looks at MYL over the past 5-years- CLICK ON CHART TO ENLARGE Over the past year, MYL could be forming a bullish inverse head & shoulders pattern with a test of the neckline and falling resistance taking place at (1). If a breakout takes place here, it could attract buyers to this hard-hit stock. Another thing that catches our attention is the large unfilled gap that took place back in 2015 at the $65 zone. Often times “Gaps” end up getting filled. If this gap would get filled, MYL would make some nice gains from current levels. Full Disclosure- Members are long this stock with a tight stop. Chart pattern analysis with brief commentary: There is a ton of news and opinions about markets and stocks that make the decision-making process more difficult than it needs to be. I believe the Power of the chart Pattern provides all you need to see what is taking place in an asset and determine the action to take. This approach has worked well for me and our clients and I encourage you to test it for yourself. Send an email if you would like to see sample research and take me up on a30 DAY FREE TEST DRIVE of our Premium or Weekly Research where I provide actionable alerts on breakouts and reversals in broad market indices, sectors, commodities, the miners and select individual stocks Email [email protected] Call us Toll free 877-721-7217 international 714-941-9381 Website: KIMBLECHARTINGSOLUTIONS.COM Receive daily research I post on the blog each day Follow on Twitter See our latest webinar
Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Mylan (MYL) receives approval for its biosimilar of breast cancer drug, Herceptin. Amazon is reportedly in talks with Mylan and another generic manufacturer about a potential entry in distribution of drugs.
Per reports, Amazon.com Inc. (AMZN) might venture into the prescription drug territory.
Will the $69 billion CVS Health (CVS)-Aetna acquisition trigger more such deals in the healthcare sector?
The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.
Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.